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Abstract:
Background: Myofibroblast transformation is a key step in the 
pathogenesis of Peyronie’s disease (PD). Phosphodiesterase type 5 
inhibitors (PDE5i) and selective oestrogen receptor modulators (SERMs) 
can prevent the formation of fibrosis in in vitro and in vivo models of PD. 
However, it is unknown whether these drugs can also reverse 
established fibrosis. 
Aim: To investigate whether PDE5i and SERMs can reverse transforming 
growth factor beta 1 (TGF-β1)-induced myofibroblast transformation and 
determine the point of no return. 
Methods: In-Cell ELISA (ICE) was used to quantify TGF-β1-induced 
myofibroblast transformation of human primary fibroblasts isolated from 
tunica albuginea (TA) of patients undergoing surgery for treatment of 
PD. ECM production and collagen contraction assays were used as 
secondary assays. Reverse transcription quantitative polymerase chain 
reaction (RT-qPCR) and ICE were utilised to measure drug target 
expression. PDE5i (vardenafil) and SERM (tamoxifen) were applied at 
various time points following TGF-β1. 
Outcomes: Reversibility of myofibroblast transformation and drug target 
expression were investigated in a time dependent manner in TA-derived 
fibroblasts 
Results: Vardenafil or tamoxifen could not reverse the myofibroblast 
traits of alpha-smooth muscle actin (ASMA) expression and extracellular 
matrix production, whilst only tamoxifen affected collagen contraction 
after 72h of TGF-β1 treatment. PDE5A and Oestrogen receptor (ER)-β 
were downregulated after 72h, ER-α protein could not be quantified. 
Tamoxifen could prevent myofibroblast transformation until 36h after 
TGF-β1 treatment, vardenafil only 24h after TGF-β1 treatment. This was 
mirrored by downregulation of drug targets on mRNA and protein level. 
Further anti-fibrotic signalling pathways, peroxisome proliferator-
activated receptor gamma (PPARy) and betaglycan (TGFBRIII), were 
significantly downregulated after 36h of TGF-β1 exposure, as opposed to 
upregulation of pro-fibrotic thrombospondin-1 (THSB-1) at the same 
time point. 
Clinical Translation: This study suggests that using PDE5i and SERMs 
might only help for early phase Peyronie’s disease and further highlights 
the need to test drugs at the appropriate stage of the disease based on 
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their mechanism of action. 
Strengths & Limitations: The study utilises primary human TA-derived 
fibroblasts which enhances translatability of the results. Limitations 
include that only one example of PDE5i- and SERM- type drug was 
tested. Time course experiments were only performed for marker 
expression experiments and not for functional assays. 
Conclusion: This is the first study to demonstrate that timing for 
administration of drugs affecting myofibroblast transformation appears 
to be vital in in vitro models of Peyronie’s disease, where 36h of TGF-β1 
treatment can be suggested as a “point of no return” for myofibroblast 
transformation.
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Phosphodiesterase type 5 inhibitors and selective oestrogen receptor 
modulators can prevent but not reverse myofibroblast transformation in 
Peyronie’s disease
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Background: Myofibroblast transformation is a key step in the pathogenesis of Peyronie’s disease 
(PD). Phosphodiesterase type 5 inhibitors (PDE5i) and selective oestrogen receptor modulators 
(SERMs) can prevent the formation of fibrosis in in vitro and in vivo models of PD. However, it is 
unknown whether these drugs can also reverse established fibrosis. 
Aim: To investigate whether PDE5i and SERMs can reverse transforming growth factor beta 1 (TGF-
β1)-induced myofibroblast transformation and determine the point of no return.
Methods: In-Cell ELISA (ICE) was used to quantify TGF-β1-induced myofibroblast transformation of 
human primary fibroblasts isolated from tunica albuginea (TA) of patients undergoing surgery for 
treatment of PD. ECM production and collagen contraction assays were used as secondary assays. 
Reverse transcription quantitative polymerase chain reaction (RT-qPCR) and ICE were utilised to 
measure drug target expression. PDE5i (vardenafil) and SERM (tamoxifen) were applied at various 
time points following TGF-β1.
Outcomes: Reversibility of myofibroblast transformation and drug target expression were 
investigated in a time dependent manner in TA-derived fibroblasts
Results: Vardenafil or tamoxifen could not reverse the myofibroblast traits of alpha-smooth muscle 
actin (ASMA) expression and extracellular matrix production, whilst only tamoxifen affected collagen 
contraction after 72h of TGF-β1 tr atment. PDE5A and Oestrogen receptor (ER)-β were 
downregulated after 72h, ER-α protein could not be quantified. Tamoxifen could prevent 
myofibroblast transformation until 36h after TGF-β1 treatment, vardenafil only 24h after TGF-β1 
treatment. This was mirrored by downregulation of drug targets on mRNA and protein level. Further 
anti-fibrotic signalling pathways, peroxisome proliferator-activated receptor gamma (PPARy) and 
betaglycan (TGFBRIII), were significantly downregulated after 36h of TGF-β1 exposure, as opposed to 
upregulation of pro-fibrotic thrombospondin-1 (THSB-1) at the same time point. 
Clinical Translation: This study suggests that using PDE5i and SERMs might only help for early phase 
Peyronie’s disease and further highlights the need to test drugs at the appropriate stage of the disease 
based on their mechanism of action.
Strengths & Limitations: The study utilises primary human TA-derived fibroblasts which enhances 
translatability of the results. Limitations include that only one example of PDE5i- and SERM- type drug 
was tested. Time course experiments were only performed for marker expression experiments and 
not for functional assays.
Conclusion: This is the first study to demonstrate that timing for administration of drugs affecting 
myofibroblast transformation appears to be vital in in vitro models of Peyronie’s disease, where 36h 
of TGF-β1 treatment can be suggested as a “point of no return” for myofibroblast transformation. 
KEYWORDS: Myofibroblast transformation, Peyronie’s disease, transforming growth factor, anti-
fibrotic therapies, PDE5i, SERM
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Fibrosis is defined as the excess accumulation of extracellular matrix (ECM) proteins in response to 
chronic injury or inflammation [1]. Fibrotic disorders encompass a wide range of clinically relevant 
diseases, affecting any organ or system in the body, such as skin, liver, kidney or lung [2–5]. Peyronie’s 
disease (PD) is characterised by the formation of a fibrotic plaque in the penile tunica albuginea (TA) 
leading to pain, curvature and erectile dysfunction [6]. Despite affecting 0.3-9% of men worldwide [7–
9], current medical treatment is very limited. Specifically, there are no approved drugs for the early, 
unstable phase of PD. To aid drug development endeavours and pre-clinical research, in vitro 
modelling of PD has often been attempted by using TA-derived fibroblasts from patients suffering 
from PD.
Myofibroblasts are highly contractile and proliferative, alpha-smooth muscle actin (ASMA) positive, 
ECM producing cells. They are derived from quiescent tissue resident fibroblasts [10] and play a key 
role in the formation and pathophysiology of PD and fibrosis in general [11]. Whilst being vital in the 
physiological wound healing response, they are responsible for the plaque formation and subsequent 
contraction in PD [12,13]. Furthermore, due to their role as main modulators of tissue remodelling 
and matrix homeostasis, they have been described as critical effectors in fibrosis where their 
persistence leads to resistance to apoptosis [14,15]. Whilst multiple origins of the myofibroblast have 
been proposed, the most common source remain locally resident fibroblasts undergoing 
transformation to myofibroblasts [16]. 
TGF-β1 is a crucial regulator of fibroblast phenotype and function and is the main effector cytokine in 
myofibroblast transformation [17]. The canonical signalling pathway for TGF-β1 activates SMAD 
(Mothers against decapentaplegic homolog) transcriptional activator-dependent which  regulate 
myofibroblast transformation by directly influencing the expression of ACTA2, the gene for the 
myofibroblast marker ASMA [18]. Additionally, TGF-β1 can act via non-canonical ways, independent 
of Smad signalling and through crosstalk with other signalling pathways [19,20].
Along with directly targeting TGF-β1-signalling, the inhibition of myofibroblasts has been suggested as 
a therapeutic approach and recent research has focused on preventing their formation [21–23]. 
Previously the anti-fibrotic effect of phosphodiesterase type 5 inhibitors (PDE5i) and selective 
oestrogen receptor modulators (SERMs) has been demonstrated in models of PD [23]. This study 
showed that PDE5i and SERMs were able to prevent TGF-β1-induced myofibroblast transformation on 
a phenotypic (reduced ASMA expression) and functional level (reduced ECM formation and contractile 
ability) in TA-derived cells. However, this study did not address whether the drugs had the ability to 
reverse already formed fibrosis, e.g. by inducing dedifferentiation, which has been proposed as a 
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promising alternative in facing the challenges of drug development to tackle fibrotic diseases [24].  
Several agents have been reported to achieve a return to non-myofibroblast state, such as capsaicin 
[25], CU/Zn SOD [26], or S-nitrosothiols [27] but no study has looked at the direct influence of TGF-β1 
exposure time on preventing myofibroblast transformation when testing drugs. It is unclear whether 
drug treatment targeting myofibroblasts might even be more successful during the process of 
myofibroblast differentiation, as opposed to before or after. Consequently, the primary aim of this 
study was to investigate whether the previously discovered anti-myofibroblast effect of PDE5i and 
SERMs is limited to preventing myofibroblast transformation or whether they can also reverse already 
formed myofibroblasts. A second aim was to investigate the efficacy of PDE5i and SERMs after various 
times of TGF-β1 exposure and determine a point of no return after TGF-β1 treatment, where it has 
become impossible for the drugs to reverse or prevent the myofibroblast state. 
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Tunica albuginea (TA) tissue samples that would have otherwise been surgical discarded were 
acquired from patients undergoing corrective surgery for PD at XXXXXX Hospital (XXX), XXXXX. Non-
plaque TA was obtained from PD patients undergoing a Nesbit procedure whereby non-fibrotic TA 
tissue was excised from the opposite side of the plaque.  The patients enlisted for this study were aged 
between 18 and 75, able to understand the patient information sheet and to give written consent. 
Ethical approval was obtained by independent research ethics committees (XXXXXXX and XXXXX). 
Isolation of fibroblasts from TA tissue
Isolation of fibroblasts was performed as previously described [22,23]. Tissue samples were dissected 
into small pieces to ensure corpus cavernosum was removed, submerged in culture media (DMEM 
(GIBCO, Invitrogen, Waltham, Massachusetts, United States), 10% FCS (Fisher Scientific, 
Loughborough, United Kingdom), 1%Pen/Strep (GIBCO, Invitrogen) in 6-well plates and incubated at 
37°C, 5% CO2 in a humidified atmosphere for 5-7 days until cellular outgrowth was observed. Tissue 
was removed and cells were washed with PBS and fresh, warm medium was added. Cells were 
incubated at 37°C until they reached 50-70% confluence, after which cultures were expanded. Cells 
were characterised as previously described[22,23]. Briefly, cells were subjected to RT-qPCR, 
Immunocytochemistry, In-Cell ELISA, and Western blot to measure expression of mesenchymal 
marker vimentin, in absence of smooth muscle marker desmin with expression of myofibroblast 
marker ASMA in TGF-β1 concentration dependent manner. Passages 2-6 were used throughout these 
experiments.
In-Cell ELISA (ICE)
The expression of ASMA and other protein markers was quantified in 96-well plates using the In-Cell 
ELISA (ICE) technique, as previously described [22,23]. Fibroblasts were either untreated or pre-
treated with 10ng/mL of TGF-β1 for 72h to generate myofibroblast cultures. Cells were seeded onto 
96 well optical flat bottom black microplates (Nunc, Rochester, New York, United States) at 5.0 x 103 
cells /well and left overnight at 37°C, 5% CO2. Media was replaced with fresh media with and without 
TGF-β1 (10 ng/ml) for the indicated time points hours. Additionally, a SERM (tamoxifen, Sigma-Aldrich, 
Gillingham, United Kingdom) or PDE5i (vardenafil, Sigma-Aldrich, UK) was added at different 
concentrations (0.1 µM to 1,000 µM for PDE5i, 0.018 µM to 54 µM for SERM). SB-505124, a TGFBRII 
inhibitor was used as control. The compounds were dissolved in 100% DMSO to stock concentration. 
After incubation, cells were fixed using 4% paraformaldehyde for 20 minutes at room temperature, 
washed with 0.1% Triton X-100 in PBS and blocked for 90 min using 10% donkey serum plus 0.1% 
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Triton X-100 in PBS.  Primary antibody solution diluted in PBS (1:3,000 dilution of mouse monoclonal 
anti-ASMA antibody, 1:100 dilution of rabbit monoclonal anti-PDE5A, 1:500 dilution of rabbit 
polyclonal oestrogen receptor alpha or 1:500 dilution of rabbit polyclonal oestrogen receptor beta) 
was added and incubated for 2h at room temperature. Additionally, blocking peptides specific to 
antibodies were used to ensure specificity of antibodies. Blocking peptides were obtained by Abcam 
(Cambridge, UK). Cells were subjected to three washing steps using 0.1% Tween 20 in PBS after which 
the secondary antibody and nuclear stain were added (donkey anti-mouse or donkey anti-rabbit at 
1:500 which emits at 800 nm; IRdye 800CW; Li-COR, Cambridge, United Kingdom; nuclear counterstain 
at 1:1,000 that emits at 700 nm (DRAQ5, Biostatus, Loughborough, United Kingdom)) After 1h 
incubation,  cells were washed three times with 0.1% Tween 20 in PBS and the plate was scanned 
using an infrared imaging system (Odyssey® CLx imager, Li-Cor, UK) at both 700 nm and 800 nm 
wavelengths. 
Immunocytochemistry 
Cells were seeded into wells of a 6 well plate containing sterile glass coverslips at 5.0 x 104 cells/well. 
After overnight incubation, media was replaced with either fresh media or media containing TGF-β1 
(10 ng/mL; Sigma Aldrich UK) for 72 hours. Cells were fixed using ice cold methanol at -25°C. Coverslips 
were incubated with 10% donkey serum (Millipore, Burlington, Massachusetts, United States) in PBS 
and then with a mouse monoclonal anti-α-SMA antibody (1:1,000; Sigma Aldrich, UK), a monoclonal 
anti-vimentin antibody (1:1,000; Abcam, UK) or a monoclonal anti-desmin antibody (1:100; Abcam, 
UK). The secondary antibodies used were a donkey anti-mouse secondary antibody (1:250; Millipore, 
UK) and donkey anti-rabbit secondary antibody (1:250; Millipore, UK). Images were captured using a 
Zeiss LSM 510 confocal microscope. Images were quantified where applicable by using ImageJ 
software to assess the corrected total cell fluorescence (CTCF). The formula for CTCF can be found 
below. 
𝐶𝑇𝐶𝐹 = 𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 ― (𝑎𝑟𝑒𝑎 𝑜𝑓 𝑐𝑒𝑙𝑙 ∗ 𝑚𝑒𝑎𝑛 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑟𝑒𝑎𝑑𝑖𝑛𝑔)
 CTCF results were normalized as percentage of untreated control cells.
Collagen gel contraction assay
Cell Contraction Assay (Cell Biolabs Inc., San Diego, California, United States) was used according to 
the manufacturer’s instructions as previously described [23]. Cells were treated with 10ng/mL of TGF-
β1 prior to the experiments.  Contraction experiments lasted over a period of 8h and images were 
taken every hour using a digital camera (Canon Digital IXUS 55, 5.0 mega pixels). Image analysis was 
performed using ImageJ software, measuring the surface area of the contracting collagen lattice. 
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Contraction was calculated as percentage of the surface of the unreleased lattice. Data is shown as 
percentage of maximum contraction of vehicle control. 
ECM production assay
ECM production assays were performed as previously described [23]. Cells were treated with 10ng/mL 
of TGF-β1 prior to the experiments. Cells were seeded onto 96 well optical flat bottom black 
microplates (Nunc, Fisher Scientific, UK) at 5 x 103 cells per well. After overnight attachment, they 
were stimulated compounds for 7 days. DRAQ5 in PBS (1:1,000) was added and cells were incubated 
for 5 min at 37 °C, 5% CO2 before scanning the plate to obtain nuclear staining.  Cells were then lysed 
using ammonium hydroxide and ECM was fixed using a solution containing 50% methanol and 7.5% 
acetic acid for 1h at -20°C. Afterwards ECM was stained either with primary antibodies (collagen I, 
Abcam; collagen III, Millipore; collagen V, Abcam: fibronectin, Millipore) at 1:1000 for 1h on a shaker, 
followed by incubation with secondary antibody and scanning the plate using an infrared imaging 
system (Odyssey CLx imager, LI-COR, UK) at both the 700 nm and 800 nm wavelengths. Results were 
normalized to the cell number before lysis. 
RNA isolation and quality assessment
Cells were seeded into 6 well plates (Nunc, Fisher Scientific, UK) at 5.0 x 104 cells/well and incubated 
with or without 10 ng/ml TGF-β1 for the indicated time points. Total RNA was extracted from cells 
using the RNeasy Mini Kit (Qiagen, UK), according to the manufacturer’s instructions. RNA was 
resuspended in 40µL of water and stored at -80ºC. RNA was quantified using a Nanodrop 
(ThermoFisher Scientific, UK) and its integrity was assessed using an Agilent Bioanalyser (Agilent 
Scientific Instruments, Didcot, United Kingdom). All RNA samples had RIN values of 9 and above.
RT reactions
RNA extracted from two patients was used, with RNA from one patient subjected to replicate RT 
reactions. 100 ng RNA aliquots were reverse transcribed using two Reverse Transcriptases (Superscript 
IV (ThermoFisher Scientific, UK) and Ultrascript 2.0 (qPCRBio, London, United Kingdom)  in 20 µL 
reactions using random priming and conditions specified by the manufacturers’ RT protocols on a 
Thermocycler (G-Storm, Pickmere, Knutsford, Cheshire, United Kingdom) with the heated lid set to 
112 ºC. For subsequent qPCR reactions, the cDNA preparations were diluted 5-fold with RNase-free 
water.
qPCR 
qPCR assays were carried out in 5 µL reactions containing 1x SensiFast SYBR (Bioline,  London, United 
Kingdom) master mixes, with primers at 300 nmol final concentration and 1 µL of diluted cDNA. 
Thermal cyclers used were either a CFX Connect (Biorad, Watford, United Kingdom) or an Eco 
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(PCRMax, Stone, Staffordshire, United Kingdom) programmed as follows: enzyme activation at 95ºC 
for 30 seconds, followed by 40 cycles of 95ºC for 2 seconds, 60ºC for 2 seconds and 72ºC for 5 seconds, 
with fluorescence collection at 72ºC. Absence of PCR inhibition was checked by using the SPUD assay 
to detect changes in Cq with the SPUD artificial template in the reactions containing sample DNA 
compared to water controls [28].
Analysis of qPCR data
Standard curves were prepared for each assay using 10-fold serial dilutions of PCR amplicons, with 
amplification efficiencies calculated from the slopes of the dilution curves. Fold-changes were 
calculated using the ∆∆Cq method, modified to include actual amplification efficiencies  as 
recommended by the MIQE guidelines [29]. The statistical analyses for data sets were analysed and 
graphed using Prism for Mac OS X, version 9.0 (Graphpad Software, San Diego, US).
Statistical Analysis
Data analysis was performed using Microsoft Excel 2013 or GraphPad Prism 7 software. Statistical 
significance, unless otherwise stated, was calculated using one-way ANOVA and Student’s t-test for 
unpaired means (two-sided). A P value less than 0.05 was considered statistically significant. 
The differences between multiple groups in collagen contraction and time course In-Cell ELISA 
quantification experiments were compared using one-way analysis of variance (ANOVA). Student t 
test for unpaired means (two sided) was used to compare the difference between two groups in ICC 
and ICE. Prior to performing this calculation, F test of equality of variances was performed, to ensure 
that equal variance could be assumed when performing Student t test. A p value of <0.05 was 
considered statistically significant. Experiments were performed in at least three independent times 
using samples from at least 3 patients in triplicate wells (N=3). Cells derived from the same three 
patients were used in all experiments. Results from all experiments were pooled, and the mean values 
and standard errors of mean were used for statistical analysis.
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PDE5i and SERM cannot reverse TGF-β1 induced myofibroblast marker expression
We have previously shown that PDE5i and SERMs can prevent transformation of TA-derived 
fibroblasts to myofibroblasts in vitro [23].  The effect of PDE5i (vardenafil) and SERM (tamoxifen) on 
myofibroblast transformation in cells that have been pre-treated with TGF-β1 for 72h was investigated 
by measuring ASMA protein expression using the ICE method. After 72h of TGF-β1 treatment the cells 
were treated with varying concentrations of vardenafil or tamoxifen for 72h to assess whether the 
drugs could reverse expression of the myofibroblast marker ASMA. Figure 1A shows that an exemplar 
vardenafil only had a minor effect on the expression of ASMA and only at the highest concentration 
(1,000 µM) where a decrease in cell viability was evident. The effect of tamoxifen on ASMA expression 
in TGF-β1 pre-treated cells is illustrated in Figure 1B. A decrease in ASMA expression was only 
observed at the highest concentration of tamoxifen (54 µM) which also showed reduced cell viability. 
These results suggest that vardenafil or tamoxifen are not able to reverse myofibroblast 
transformation.
Not all myofibroblast functions can be reversed by PDE5i and SERM 
To further investigate whether the PDE5i and SERM influence the myofibroblast functions, the effect 
of the drugs on the myofibroblast function was assessed. Typical myofibroblast functions include 
contraction and ECM formation [10] and functional assays to measure these have been described 
previously [23]. Cells were pre-treated with TGF-β1 for 72h in the experiments shown in Figures 2 and 
3. The effect of vardenafil, tamoxifen, and a TGFBRII inhibitor (SB-505124) on production of ECM 
components collagen I, III, V, and fibronectin is shown in Figure 2. Neither the PDE5i nor the SB-505124 
compound had any effect on ECM formation at any concentration (Figure 2A-D), whereas the 
tamoxifen only had an effect at the highest concentration which has previously been shown to affect 
cell viability. Collagen contraction assays were utilised to further assess the effect of vardenafil and 
tamoxifen on myofibroblast function in cells pre-treated with TGF-β1.  The TGFBRII inhibitor SB-
505124 did not inhibit contraction of myofibroblast-populated collagen lattices (MPCL) at any 
concentration over the course of the experiment (Figure 3A). The same observation could be made 
for the vardenafil, that did not decrease the contraction at any concentration over 8h (Figure 3B). 
Surprisingly, any of the tested tamoxifen concentrations (1, 3, 10 µM) caused a significant (p<0.05) 
decrease in collagen lattice contraction over the course of 8h (Figure 3C).
Completed myofibroblast transformation leads to downregulation of drug targets
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To elucidate whether this lack of anti-myofibroblast activity is related to the expression of the drug 
targets, the expression of PDE5A and oestrogen receptor (ER) α and β was compared between 
untreated TA-derived fibroblasts and cells exposed to TGF-β1 for 72h. The ICE method was used in 
conjunction with antibody-specific blocking peptides to quantify protein expression reliably (Figure 4), 
whereas ICC was used to confirm the findings (Supplementary Figure 1).  TGF-β1 exposure caused a 
significant (p<0.05) downregulation of PDE5A in TA-derived fibroblasts compared to untreated cells 
(Figure 4 A, B; Suppl Fig 1A-C). MCF7 cells were used as a positive control and showed expression of 
PDE5A, whereas the blocking peptide confirmed specificity of the antibody against PDE5A (Figure 4A, 
B). Expression of ER-α could not be detected on protein level in TA-derived fibroblasts that were 
untreated or treated with TGF-β1 for 72h and could only be shown in the positive control MCF7 (Fig 
4C; Suppl Fig 1D,E,F). Protein expression of ER-β was significantly downregulated (p<0.05) in TA-
derived fibroblasts after 72h of TGF-β1 exposure (Figure 4C, F; Suppl Fig 1G,H,I). Specificity of the 
antibody was ensured via the antibody-specific blocking peptide (Figure 4C). MCF7 cells were used for 
ICC as positive control for PDE5A and ER-β (Suppl Fig 1 J, K).
Effect of PDE5i and SERMs on myofibroblast transformation after limited TGF-β1 exposure
To assess whether there was a specific timepoint between initial TGF-β1 exposure and fully completed 
myofibroblast transformation at which PDE5i or SERMs could affect or reverse ASMA expression, time 
course experiments were performed. It is known that myofibroblast transformation requires a total 
of 72h for completion [30]. To this end, cells were treated with TGF-β1 for 24h, 36h, or 48h after which 
it was removed and replaced with one of the drugs for the rest of the 72h incubation. To ensure that 
limited exposure to TGF-β1 would still lead to complete myofibroblast transformation, TA-derived 
fibroblasts were used and TGF-β1 was removed after 24h, 36h, 48h, 72h after which ASMA expression 
was quantified at the end of the 72h period (Supplementary Figure 2). As can be seen, there was no 
difference in ASMA expression between the different time points, meaning only the initial 24h 
exposure to TGF-β1 is needed to complete full myofibroblast transformation within a 72h period, so 
cells don’t need to be exposed to TGF-β1 for the entire 72h. 
Figure 5 depicts the effect of PDE5i on myofibroblast transformation after different TGF-β1 exposure 
times. When only treated with TGF-β1 for 24h, a subsequent 48h incubation with vardenafil caused a 
decrease of ASMA expression, as is evidenced by the inverse sigmoid curve with upper and lower 
plateau in Figure 5A. PDE5i treatment could not prevent ASMA expression after 36h or 48h of TGF-β1 
exposure (Figure 5B,C).
Tamoxifen could be shown to affect myofibroblast transformation after 24h and 36h of TGF-β1 
exposure (Figure 6A,B) but not after 48h (Figure 6C). The anti-myofibroblast effect seen when using 
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5.4, 18 and 54µM of tamoxifen gradually gets weaker with longer TGF-β1 pre-treatment. While the 
highest concentration (54µM) still had some effect (9% inhibition) after 48h of TGF-β1 treatment, 
lower concentrations did not inhibit ASMA expression anymore.
To confirm the findings, a complete time course of TGF-β1 with SB-505124 was performed (Suppl Fig 
3). SB-505124 has previously been shown to prevent myofibroblast transformation in vitro [31]. In our 
setting, SB-505124 was incapable of affecting ASMA expression in cells that were pre-treated with 
TGF-β1, regardless of dose or treatment time point, confirming that main response to TGF-β1 
signalling takes place within the first 24h. 
Time course experiments suggest point of return for myofibroblast transformation is after 36h
To further investigate the effect of TGF-β1 on the expression of drug targets for PDE5i and SERMs, 
cells were exposed to TGF-β1 for varying time points and mRNA levels of specific genes were 
quantified and compared to untreated cells. GAPDH was validated as a suitable reference gene, as 
its expression varied little between control samples and those subjected to TGF-ß1 treatment RNA 
samples, as shown in Supplementary Figure 4. ACTA, the gene for ASMA, was significantly 
upregulated at 24h, 36h, 48h, and 72h of TGF-β1 treatment (Figure 7A). Significant downregulation 
of mRNA upon TGF-β1 treatment could be observed for PDE5A. The mRNA levels were significantly 
below the level of technical noise at any point of TGF-β1 treatment (Figure 7B). Despite not being 
able to measure protein levels of ER-α, the mRNA levels of ER1 were quantified. As can be seen in 
Figure 7C, the fold-change for expression ranged within the levels of technical noise for 24h and 36h 
treatment groups, while 48h showed significant downregulation, which returned to levels of 
technical noise after 72h (Figure7C). ER2, the gene for ER-β, showed significant upregulation of 
mRNA 24h after TGF-β1 treatment. Following 36h of TGF-β1 treatment, there was no significant 
differences compared with untreated cells (within the 3-fold level for technical noise), while ER2 
mRNA was significantly downregulated after 48h and 72h of TGF-β1 treatment (Figure 7D).
These findings were complemented with protein quantification using ICE. ASMA, PDE5A and ER-β 
were quantified after exposing cells to TGF-β1 for 24h, 36, 48h and 72h. Whilst  mRNA was 
upregulated after 24h, protein levels of ASMA were only significantly upregulated (p<0.05) after 36h 
and reached their maximum after 72h (Figure 7E), with no significant differences between 48h and 
72h. This suggests that its transcriptional and translational regulation are decoupled. In contrast, the 
protein levels of PDE5A were immediately significantly reduced (p<0.05) after 24h (Figure 7F), in line 
with the significantly lower levels of mRNA. Longer TGF-β1 treatment lead to further reduction, as 
levels after 36h were significantly lower compared to 24h and levels after 72h after significantly lower 
than after 36h and 48h. As the cells utilised in these experiments do not seem to express ER-α (Figure 
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4, Suppl Fig 1), only levels of ER-β were quantified. Protein levels of ER-β were significantly reduced 
(p<0.05) after 48h and 72h compared to untreated cells, whilst there appeared to be a trend for 
reduced expression after 36h that did not reach significance (Figure 7G. 
Gene expression analysis reveals three additional genes with differential regulation after 36h
Since the protein data for ASMA, PDE5A and ER-β suggested a significant event between 36h and 48h, 
further pro- and anti-fibrotic signalling pathways were investigated via RT-qPCR. GAPDH was validated 
as reference gene (Suppl Fig 4). A panel of various marker genes was interrogated (Figure 8, Suppl Fig 
5). Three genes were found to follow the pattern of 36 h point of no return: peroxisome proliferator-
activated receptor-γ (PPARγ), transforming growth factor beta receptor III (TGFBRIII) and 
thrombospondin-1 (THSB-1). Figures 8A and B depict the expression of PPARγ and TGFBRIII at various 
time points after TGF-β1 exposure. Both genes were significantly downregulated after 36h, 
strengthening the case for a point of no return after 36h of TGF-β1 treatment. The gene for TSP-1 
(THSB-1) was significantly upregulated after 36h of TGF-β1 treatment (Figure 8C). The other markers 
tested in this study were either unchanged (BIRC5, GPER2) over the entire time course, or significantly 
upregulated (IGF1, IGFBP3) or downregulated (GPER4) 48h after TGF-β1 insult (Suppl Fig 5).
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This study reports two major findings (1) the anti-fibrotic effects of PDE5i and SERM are dependent 
on the time of TGF-β1-exposure, as longer TGF-β1-exposure leads to a decrease in drug efficacy (2) 
there is a point of no return, which occurs around 36h after TGF-β1 treatment that can be delineated 
by up- and downregulation of key marker proteins and genes. 
Previously both PDE5i and SERMs have been suggested as a treatment for PD [32–37]. We have shown 
that the combination of both drug classes exerted a synergistic effect in preventing myofibroblast 
transformation [23]. Interestingly, in our experiments, PDE5i treatment did not reduce ASMA 
expression in cells pre-treated with TGF-β1 for longer than 24h. This indicates that the drugs can 
inhibit myofibroblast transformation only at the start of the process and cannot reverse it. It also 
contradicts a previously published result, where treatment using various concentrations of vardenafil 
could reverse TGF-β1-induced prostate-derived myofibroblast state [38]. However, that study did not 
quantify protein levels and cells were treated in the same culture dish for a total of 144h in presence 
of 1 ng/mL of TGF-β1. In contrast, our protocol included a 72h pre-treatment period with 10 ng/ml 
TGF-β1 after which cells were seeded onto appropriate plates for treatment with PDE5i or SERM. This 
difference makes any comparison difficult and could explain differences in outcomes between the 
studies. Myofibroblast function such as contraction and ECM formation were also unaffected by PDE5i 
treatment, which is conclusive in the context of PDE5i preventing rather than reversing myofibroblast 
transformation.
Previously it has been suggested that TA-derived myofibroblast transformation can be prevented by 
oestrogen signalling through inhibition of Smad and Rho [39]. Previous studies have reported SERMs 
as a potential anti-fibrotic treatment strategy with evidence gathered from in vitro and in vivo models 
suggesting reduction of hepatic [40] and renal [41] fibrosis while improved wound healing could be 
observed in skin fibrosis [42].  Mechanistically, it has been proposed that in rats SERMs decrease the 
production of TGF-β1 [43] and inhibit the canonical Smad signalling in mice thereby suppressing 
myofibroblast transformation [44]. Furthermore, a non-Smad mechanism of action  has been 
proposed via targeting of ERK1/2 and AP-1 transcription factor signalling in primary human skin 
fibroblasts [45]. Given that these suggested mechanisms all involve pathways that are critical for the 
induction of myofibroblast transformation but are not indispensable for the maintenance of the 
myofibroblast state, our observations in the time course experiments (prevention until the 36h mark) 
can be partially explained.     
However, the data of the functional collagen contraction assay needs a more critical review. It was 
unexpected to observe that tamoxifen was able to influence collagen contraction after TGF-β1 pre-
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treatment, in context of the potential mechanism of action (preventing rather than reversing 
myofibroblast transformation as outlined above). As the other myofibroblast hallmarks of ASMA 
expression (an important contractile feature) and ECM production have not been reversed by SERM 
treatment, it is reasonable to conclude that inhibition of contraction alone is not sufficient evidence 
to suggest that myofibroblast transformation was reversed. We thereby hypothesize that tamoxifen 
affected only the contractile mechanism of the cells, without actually reversing their myofibroblast 
state. The literature provides examples for SERM influencing collagen contraction [46,47]. Further, 
utilising cells derived from palmar fascia of Dupuytren’s disease and control patients, it could be 
shown that tamoxifen was able to inhibit the contraction of the cells in both, fibrotic and non-fibrotic 
settings [48]. Others used fibroblasts from Dupuytren’s disease and carpal tunnel affected fascia and 
observed a higher basal level of contraction in the diseased cells indicating higher myofibroblast 
baseline count [49]. This study demonstrated an inhibition of contraction after SERM-treatment which 
was ascribed to a decrease in TGF-β2 expression. Mechanistically, it has been proposed that treatment 
with SERM leads to a change of morphology that results in a lack of contraction in cells such as 
fibroblasts [46] but also cancer cells [50,51]. Mechanical inactivation of fibroblast-like cells by 
tamoxifen has been described to be mediated via GPER/RhoA with subsequent inactivation of YAP 
[52]. Given the downregulation of ERs after 72h of TGF-β1 treatment, the possibility of an additional, 
ER-independent or GPER-driven mechanism of SERM that mainly affects cell morphology, cytoskeletal 
makeup (rearrangement of intermediate and actin filaments/stress fibres [50]), or mechanosensing of 
the cells to prevent contraction cannot be excluded.
Collectively, the data point towards PDE5i and SERMs only preventing but not reversing TGF-β1-
induced myofibroblast transformation of TA-derived cells in vitro. To investigate potential underlying 
reasons for this effect, the expression of drug targets was quantified in a TGF-β1 and time-dependent 
manner. We hypothesized that exposure to TGF-β1 would lead to a downregulation of PDE5A and ER 
α and β, which would prevent the drugs from exerting their anti-fibrotic action due to a lack of drug 
target availability.  
Our results demonstrate that TGF-β1 induces a significant downregulation of PDE5A on mRNA and 
protein level after 72h of TGF-β1 treatment, which may explain the loss of PDE5i efficacy caused by 
lack of target expression following TGF-β1 exposure. Interestingly, whilst the mRNA downregulation 
is already apparent after 24h, the most significant downregulation of PDE5A protein appears after 
36h, which coincides with a more significant upregulation of ASMA protein levels.  Expression of PDE 
isoforms PDE4 and PDE5 could previously be determined in fibroblast cultures established from 
human PD plaques, normal TA, and rat TA [53]. Our data are in conflict with a previous study 
conducted by Zenzmaier et al that examined the consequences of lentivirus mediated shRNA 
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knockdown of PDE5 in prostate-derived fibroblasts [38]. That study reported that loss of PDE5 lead to 
a reversal of the myofibroblast state, while we consider the loss of PDE5 as a marker for myofibroblast 
transformation. Expression of PDE5 has been reported in both rat and human fibroblasts where it was 
shown that cells at higher passage, which are more susceptible to spontaneous myofibroblast 
transformation, show a decreased PDE5 expression [54]. Further one study showed that TGF-β1 
treatment lead to a significant downregulation of PDE5A protein expression in HFL-1 cells (roughly 
50% reduction) [55], which corroborates our expression results and thereby implies the loss of PDE5i 
efficacy after TGF-β1 pre-treatment is caused by lack of target expression. 
Whilst we can detect expression of ER-α and ER-β mRNA in our primary fibroblasts, only ER-β is 
expressed at the protein level. This narrows down the potential drug target of SERMs in TA-derived 
fibroblasts. Protein expression of ER-α could only be demonstrated in MCF7 (a breast cancer cell line 
isolated from a Caucasian woman) cells which have been reported to express ER-α mRNA and protein 
[56]. This is in line with previous studies that showed expression of ER-β only in adult human mammary 
fibroblasts in absence of ER-α[57]. Exposure to TGF-β1 for 72h leads to a significant downregulation 
of ER-β at the protein level. 24h of TGF-β1 lead to a significant upregulation of ER-β mRNA which did 
not translate to protein level but could be an attempt of the cell to compensate for or counteract the 
TGF-β1 signalling. During the time course of TGF-β1 treatment it was indicated that expression of the 
receptor was significantly downregulated after 48h both on mRNA and protein level, which explains 
why tamoxifen still had a minor effect on myofibroblast transformation after 36h of TGF-β1 exposure.
Collectively, this supports the hypothesis of TGF-β1-mediated downregulation of the drug targets as 
the main reason for PDE5i and SERMs being unable to reverse full myofibroblast transformation which 
is reinforced by the observations of the drugs being able to prevent myofibroblast transformation until 
the expression of the drug targets is too low (after 36h for PDE5i, 48h for SERMs). Further, the lack of 
ER-α expression suggests that the anti-fibrotic effect of SERMs may be mediated via ER-β related 
signalling, a notion supported by evidence in breast cancer in general [58] and reports of the tamoxifen 
response in ER-α negative cancer being ER-β dependent [59]. In turn, others reports suggest that 
tamoxifen acts through other intracellular signalling cascades, independent of ER-mediated signalling, 
such as Smad, ERK [44] [45] or the suppression of TGF-β1 transcription [43]. Studies into the precise 
mechanism of action are needed to resolve which signalling cascade is responsible for the anti-fibrotic 
effect of SERM in TA-derived cells. 
The results of our study may have clinical implications, as they suggest that treatment with PDE5i or 
SERMs may be useful in patients with early stage PD and that fully formed plaques are unlikely to be 
affected by either treatment, as myofibroblast elimination or reversal cannot be achieved.  Fibrotic 
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conditions such as PD are characterised by their relatively slow progression, which poses an inherent 
issue for early treatment. However, reports suggest that patients do present at earlier stages (within 
the first three months) and not just with fully formed plaques [60–62].  
The significant downregulation of key antifibrotic proteins and upregulation of myofibroblast markers 
at 36h lead us to use RT-qPCR to investigate the expression of additional genes involved in the fibrotic 
process. In doing so, our study is the first one to try and establish a point of no return in TGF-β1-
induced myofibroblast transformation. 
We analysed a panel of genes that are involved in the fibrotic process and that were differentially 
regulated after TGF-β1 treatment. Within this panel of pro- and anti-fibrotic genes, we observed genes 
that were unchanged (BIRC5, GPER2), immediately strongly upregulated (IGF1, IGFBP3) and 
downregulated after 48h. Additionally, we observed that three genes had a differential expression 
pattern after 36h: PPARγ, TGFBRIII, and THSB-1 which followed the pattern of point of no return we 
have described above. These three genes have strong evidence of influence in the fibrotic process. 
We have shown that PPARγ and TGFBRIII mRNA levels were significantly decreased 36 hours after TGF-
β1 exposure. Decreased PPARγ levels have been suggested as potential biomarker in skin fibrosis [63], 
whilst the anti-fibrotic effects of L-carnitine, a drug suggested as treatment for PD [64], are derived 
from its ability to upregulate PPARγ [65]. Further, PPARγ agonists have been demonstrated to 
decrease fibrotic responses by opposing TGF-β1 pro-fibrotic signalling (including myofibroblast 
differentiation) [66]  suggesting a vital role of PPARγ in the fibrotic process. TGFBRIII has been shown 
to be downregulated in fibrotic tissue, whilst its upregulation has been proposed as an anti-fibrotic 
strategy [67]. This underlines the significance of the downregulation of the receptor after 36h of TGF-
β1 exposure, as TGFBRIII can act as an accessory co-receptor to modulate TGF-β1 signalling [68]. Our 
results showed a significant upregulation of THSB-1 mRNA 36 hours after TGF-β1 exposure. THSB-1 
perpetuates fibrotic signalling by activating latent TGF-β1 and has therefore been proposed as a target 
for anti-fibrotic therapy [69,70] and its upregulation has been reported to predict hypoxia as well as 
fibrosis [71,72]. In penile tissues, THSB-1 upregulation was attributed to fibrotic changes observed in 
post-radical prostatectomy erectile dysfunction patients [73]. The upregulation of this gene is 
therefore an important event in the development of fibrosis and, alongside the downregulation of 
anti-fibrotic genes at the same time point, further underlines the importance of the 36h mark outlined 
in this manuscript. Defining what leads to this key event that promotes pro-fibrotic genes and at the 
same inhibits anti-fibrotic genes after 36h might be a novel target to tackle not only PD but fibrosis in 
general.
Given that fibrosis has a complex pathology with multiple genes and pathways involved, it will be 
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necessary to confirm this proposed point of no return by obtaining more complete transcriptomic and 
proteomic data. This should result in the establishment of gene signatures that will help reveal the full 
mechanism underlying myofibroblast transformation and lead to the discovery of new druggable 
targets. We acknowledge this lack of high-volume experimentation as one of the limitations of this 
study, along with the lack of confirmation on protein level. Further, this study is limited by only testing 
one exemplar PDE5i and SERM and not investigating the effect the drugs might have on the expression 
of their respective targets. In addition, it is evident that all in vitro models are inherently limited in 
fully representing the complexity and physiology of fibrosis. Ideally, the data would be supported by 
both, experimentation in 3D-mulitcellular models using multi-cytokine insults, and in vivo 
experiments.  
Conclusions:
This study suggests that PDE5i and SERMs cannot reverse already formed fibrosis and should therefore 
only be used in early stage patients with PD to obtain an anti-fibrotic effect. We also demonstrate a 
point of no return for myofibroblast transformation after 36h of TGF-β1 treatment. It is worth 
investigating whether this point of no return can be a viable novel target for further drug development 
endeavours, as opposed to only preventing formation of or reversing fully formed fibrosis. Our data 
further demonstrates the need to design clinical trials that take the mechanism of action of the drug 
into account, as PDE5i and tamoxifen have only been shown to be successful in the trials that recruited 
early phase PD patients, which as this data demonstrates will respond better to the drugs. 
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Figure 1: PDE5i and SERM cannot reverse ASMA expression after 72h of TGF-β1 pre-treatment of 
TA-derived cells. A) Effect of vardenafil on ASMA expression. TA-derived cells were pre-treated with 
10 ng/mL of TGF-β1 for 72h and then exposed to various concentrations (0.1-1,000 µM) of vardenafil. 
B) Effect of tamoxifen on ASMA expression. TA-derived cells were pre-treated with TGF-β1 for 72h 
and then exposed to various concentrations (0.018-54 µM) of tamoxifen. ASMA staining was 
normalised to DNA staining (cell viability). Data points were plotted as average ± SEM of ASMA/DNA 
staining ratio obtained from Odyssey infra-red imager.  N=3
Figure 2: PDE5i and SERMs do not reduce ECM production after 72h of TGF-β1 pre-treatment of TA-
derived cells. TA-derived cells were pre-treated with 10ng/mL of TGF-β1 for 72h and then exposed to 
various concentrations of vardenafil (0.03-100 µM; blue), tamoxifen (0.018-54 µM; red), or SB-505124 
(0.03-100 µM; grey). 8 days after treatment cells were lysed and ECM content was quantified. ECM 
proteins included Col I (A), Col V (B), Col III (C), and fibronectin (D). Protein was normalised to DNA 
staining before lysis. Data points were plotted as average ± SEM of protein/DNA staining ratio 
obtained from Odyssey infra-red imager.  N=3
Figure 3: SERM but not PDE5i can reduce collagen contraction after 72h of TGF-β1 pre-treatment of 
TA-derived cells. TA-derived cells were pre-treated with 10 ng/mLTGF-β1 for 72h and then exposed 
to various concentrations of A) SB-505124 (1, 3, 10 µM), B) vardenafil (10, 30, 100 µM), C) tamoxifen 
(1, 3, 10 µM). 3 days after treatment collagen lattices were released from the wall of the well and 
contraction was observed over an 8h period. Data presented as percentage of maximum collagen 
contraction compared to vehicle control (DMSO), data points plotted as mean ± SEM. Statistical 
analysis using student’s t-test with *p<0.05 vs vehicle control. N=3
Figure 4: Quantification of PDE5A, ER-α and ER-β after 72h of TGF-β1 treatment of TA-derived cells. 
TA-derived cells were left untreated or treated with 10 ng/mL of TGF-β1 for 72h. A) Quantification of 
PDE5A using ICE. Data points plotted as mean ± SEM. Blocking peptide and positive control cell line 
MCF7 used for accuracy. Statistical analysis using student’s t-test with *p<0.05 vs untreated. N=3. B) 
Quantification of ER-α using ICE. Data points plotted as mean ± SEM. Blocking peptide and positive 
control cell line MCF7 used for accuracy. Statistical analysis using student’s t-test with *p<0.05 vs 
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untreated. N=3. C) Quantification of ER-β using ICE. Data points plotted as mean ± SEM. Blocking 
peptide and positive control cell line MCF7 used for accuracy. Statistical analysis using student’s t-test 
with *p<0.05 vs untreated. N=3
Figure 5: Effect of PDE5i at various time points after TGF-β1 treatment. TA-derived cells were treated 
with TGF-β1 for 24h (A), 36h (B) or 48h (C). After indicated incubation period, TGF-β1 was removed 
and cells were treated with various concentration (0.1-1,000 µM) of vardenafil. ASMA staining was 
assessed 72h after initial TGF-β1 treatment. ASMA staining was normalised to DNA staining (cell 
viability). Data points were plotted as average ± SEM of ASMA/DNA staining ratio obtained from 
Odyssey infra-red imager.  N=3 
Figure 6: Effect of SERM at various time points after TGF-β1 treatment. TA-derived cells were treated 
with TGF-β1 for 24h (A), 36h (B) or 48h (C). After indicated incubation period, TGF-β1 was removed 
and cells were treated with various concentration (0.018-54 µM) of tamoxifen. ASMA staining was 
assessed 72h after initial TGF-β1 treatment. ASMA staining was normalised to DNA staining (cell 
viability). Data points were plotted as average ± SEM of ASMA/DNA staining ratio obtained from 
Odyssey infra-red imager.  N=3 
Figure 7: Effect of TGF-β1 exposure time on mRNA and protein expression of ASMA, PDE5A and ERs. 
TA-derived cells were treated with TGF-β1 for 24h, 36h, 48h or 72h. Expression of mRNA was assessed 
for ACTA (A), PDE5A (B), ER1 (C), and ER2 (D). Expression patterns of genes at 24h, 36h, 48h and 72h. 
Results are plotted as expression fold difference compared to t=0 in response to TGF-ß relative to the 
expression of the reference gene GAPDH. Pink horizonal lines mark the 3-fold up- or down-regulation 
levels, as previously suggested as limits of significance.  Each time point represents the mean fold 
difference ± range. Protein expression of ASMA (E), PDE5A (F) and ER-β (G) was quantified. ICE was 
used to determine Protein/DNA staining ratio. Data points were plotted as average ± SEM of 
ASMA/DNA staining ratio obtained from Odyssey infra-red imager. Statistical analysis performed using 
one-way ANOVA with multiple comparisons. *p<0.05 vs control column. #p<0.05 vs 24h column. N=3.
Figure 8: Effect of TGF-β1 exposure on various target genes. Expression patterns of PPARγ (A), TGFß-
R3 (B) and ThsB (C) at 24h, 36h, 48h and 72h. Results are plotted as expression fold difference 
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compared to t=0 in response to TGF-ß relative to the expression of the reference gene GAPDH. Pink 
horizonal lines mark the 3-fold up- or down-regulation levels, as previously suggested as limits of 
significance.  Each time point represents the mean fold difference ± range.
Supplementary Figure 1: Immunocytochemistry to confirm In-Cell ELISA protein quantification. TA-
derived cells were left untreated or exposed to 10 ng/mL of TGF-β1 for 72h. Protein of interest stained 
in green, nuclear staining in red. Representative images of PDE5A stainings captured at 200x 
magnification for untreated cells (A) and TGF-β1 treated cells (B). (C) Quantification of PDE5A 
stainings. Three independent images were quantified. Statistical analysis using Students t-test with 
*p<0.05. Representative images of ER-α stainings captured at 200x magnification for untreated TA-
derived cells (D), TGF-β1 treated TA-derived cells (E) and positive control cell line MCF7 (F). 
Representative images of ER-β stainings captured at 200x magnification for untreated cells (G) and 
TGF-β1 treated cells (H). (I) Quantification of ER-β stainings. Three independent images were 
quantified. Statistical analysis using Students t-test with *p<0.05. (J, K) Positive control cell line MCF7 
stained for PDE5A (J) and ER-β (K). 
Supplementary Figure 2: Effect of TGF-β1 removal in 72h incubation period. Cells were treated with 
TGF-β1 the day after seeding. TGF-β1 was removed after 24h, 36h, 48h, or 72h and ASMA protein 
expression was quantified 72h after the initial exposure. ASMA expression was normalised to DNA 
staining and data points plotted as mean ± SEM of ASMA/DNA staining ratio obtained from Odyssey 
infra-red imager.  N=3 
Supplementary Figure 3: Effect of SB-505124 at various time points after TGF-β1 treatment. TA-
derived cells were treated with TGF-β1 for 24h (A), 36h (B), 48h (C), or 72h. After indicated incubation 
period, TGF-β1 was removed and cells were treated with various concentration (0.03-100 µM) of SB-
505124. ASMA staining was assessed 72h after initial TGF-β1 treatment. ASMA staining was 
normalised to DNA staining (cell viability). Data points were plotted as average ± SEM of ASMA/DNA 
staining ratio obtained from Odyssey infra-red imager.  N=3 
Supplementary Figure 4: Verification of GAPDH as valid housekeeping gene. Column bar graph of 
GAPDH expression at various time points after TGF-ß treatment relative to the no treatment control. 
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Duplicate PCR assays were performed on RT reactions carried out in duplicate on RNA extracted from 
one individual and a third RT reaction carried out on RNA extracted from a second individual. Each bar 
represents the mean Cq difference ± SD.
Supplementary Figure 5: Additional marker genes investigated in TGF-β1 time course experiments. 
Expression patterns of GPER4 (A), BIRC5 (B) and GPER2 (C), IGF1 (D) and IGFBP3 (E) at 24h, 36h, 48h 
and 72h. Results are plotted as expression fold difference compared to t=0 in response to TGF-ß 
relative to the expression of the reference gene GAPDH. Pink horizonal lines mark the 3-fold up- or 
down-regulation levels, as previously suggested as limits of significance.  Each time point represents 
the mean fold difference ± range.
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